UNSPSC 51291702: Cericlamine

This classification denotes a serotonin agonist with the molecular formula C12H17Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VES82D23IB, chemically known as 2-(3,4-dichlorobenzyl)-2-dimethylamino-1-propanol but generally known as cericlamine, which bears US NIH Compound Identifier 131073. European Medicines Agency schedules Cericlamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07439MIG. The term CERICLAMINE is an International Non-Proprietary Name.

UNSPSC 51291702 Cericlamine is a Commodity code that encompasses pharmaceutical products and drug formulations procured by state and local health agencies, though recent activity under this code reflects broader pharmaceutical and health-related supply procurement rather than cericlamine specifically. State and local governments soliciting under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that serve state agencies and local government facilities. The scope of work spans generic pharmaceuticals, over-the-counter products, and specialized health interventions such as naloxone and drug deactivation systems, with vendors required to meet Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and FDA requirements including specified shelf-life minimums.

Recent activity appears concentrated in Florida and multi-state cooperative arrangements anchored in Minnesota and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023; the contract includes a two-year initial term with a one-year renewal option and carries potential FEMA funding with associated federal compliance requirements. The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026, and evaluation weighted heavily toward price competitiveness (75 percent) with insurance requirements including $5 million commercial general liability and $2 million network security and privacy liability. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs, reflecting early-stage state procurement strategy development in pharmaceutical supply chain management.